Carvykti shows promise before multiple myeloma; two megarounds; AstraZeneca wins twice
THE SO WHAT
Carvykti wiping out high-risk smoldering myeloma in 20 of 20 patients is a line-crossing moment—cell therapies are moving from last-resort to earlier intervention. For operators in oncology and biomanufacturing, capacity planning and payer negotiation need to assume front-line use cases, not niche salvage therapy volumes.
READ THE SOURCE
MORE FROM THE WIRE
Deep & Emerging TechThe DJI Power 1000 Mini portable power station just launched. But not for U.S. shoppers.
A 1,008 Wh pack at roughly $467 shows how fast portable storage is commoditizing — but export and market restrictions are now as important as watt-hours. If your hardware or edge-AI roadmap assumes cheap, globally available lithium storage, start modeling regional gaps and alternative suppliers.
Deep & Emerging TechWall Street’s Crypto Ambitions Dealt a Setback by Latest Hack
A ~$300 million exploit triggering a $10 billion liquidity run is exactly the tail-risk scenario compliance teams use to veto on-chain experiments. If you’re selling blockchain into regulated finance, assume a longer sales cycle and reframe around provable risk controls — insurance, circuit breakers, and real-time monitoring — or lose the window entirely.
Deep & Emerging TechICE’s Smart Glasses Are a Worst-Case Scenario
Smart glasses wired into biometric databases and facial recognition turn every field agent into a mobile checkpoint—this is surveillance infrastructure, not a gadget. Any company touching wearables, CV, or identity needs a governance stance now, before their tech is pulled into similar deployments by default.
Deep & Emerging Tech'Stop selling or sharing my personal information': Research finds that Big Tech could be tracking you even when you've opted out
Evidence that tracking continues after opt-out—even in states with privacy laws—sets up the next wave of enforcement and class actions. If your growth stack leans on shadow profiling, you’re now in the blast radius; shift to first-party data and auditable consent flows before regulators do it for you.